SCHEMBL5124142

SCHEMBL5124142

C#Cc1ccsc1-c1nc2cc(C)cc(C)n2c1NCC1CCCCC1.c1cc2cc-2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
ATM Q13315 1/20 0.32
TP53 P04637 1/20 0.32
MDM2 Q00987 1/20 0.32
CREBBP Q92793 2/20 0.32
ADORA3 P0DMS8 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
IRAK1 P51617 1/20 0.31
ALOX5 P09917 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAPK1 P28482 1/20 0.31
RAB9A P51151 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119833 0.92 GAA (0.40) ALDH1A1GAAKDM4EMAPTTP53
SCHEMBL5129077 0.87 ATM (0.43) ALDH1A1GAAKDM4EMAPTATM
SCHEMBL5116941 0.85 ALOX5 (0.43) ALDH1A1GAAKDM4EATMALOX5
SCHEMBL5120867 0.81 MAPT (0.36) ALDH1A1GAAKDM4EMAPTATM
SCHEMBL5127373 0.81 NR1H4 (0.38) ALDH1A1GAAKDM4EMAPTATM
SCHEMBL5128546 0.80 ALOX5 (0.41) ALDH1A1GAAKDM4EMAPTATM
SCHEMBL5122711 0.80 ALOX5 (0.41) ALDH1A1GAAKDM4EMAPTATM
SCHEMBL5122919 0.79 NR1H4 (0.43) ALDH1A1GAAKDM4EMAPTTP53
SCHEMBL5124879 0.77 GAA (0.38) ALDH1A1GAAKDM4EMAPTTP53
SCHEMBL5122906 0.77 NR1H4 (0.40) GAAMAPTTP53CREBBPMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS ALDH1A1 2777/4885GAA 234/4885KDM4E 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.